This version of the consensus statement includes the following important updates.
PBS listing of glecaprevir plus pibrentasvir
Glecaprevir plus pibrentasvir is a pan-genotypic regimen that was listed on the PBS on 1 August 2018 (glecaprevir plus pibrentasvir). Glecaprevir plus pibrentasvir is not renally excreted and is the first pan-genotypic treatment option for people with renal impairment.
TGA approval of sofosbuvir plus velpatasvir plus voxilaprevir
Sofosbuvir plus velpatasvir plus voxilaprevir is a pan-genotypic regimen that has been approved by the Therapeutic Goods Administration and is expected to be listed on the PBS in 2019 for the treatment of people who did not respond to a first-line DAA regimen (sofosbuvir plus velpatasvir plus voxilaprevir). The date of PBS listing is not yet known.
Simplified recommendations for on-treatment monitoring during DAA therapy
The recommendations for on-treatment monitoring during DAA therapy have been simplified (on-treatment monitoring).
New recommendations for the management of non-responders to DAA therapy
New recommendations for the management of people who do not respond to DAA therapy have been added (non-responders to interferon-free therapy).
New recommendations for the management of HCV in the setting of renal impairment
Recommendations for the management of people with HCV and renal impairment have been updated (special populations: treatment of HCV in people with renal impairment).